Iontophoresis Delivery System
Our proprietary technology, the EyeGate® II Delivery System, utilizes transscleral iontophoresis to deliver optimal therapeutic levels of drug directly into the targeted ocular tissue. It offers a potential alternative to current delivery modalities such as eye drops and ocular injections.
The system utilizes a low-level electrical current to deliver a specified amount of drug for each treatment. Iontophoresis is a concept that dates back to the 18th century, while the first transscleral (across the white of the eye) iontophoretic application for vitreal drug delivery was reported in 1943. The process involves applying an electrical current to an ionizable substance – one capable of carrying an electric charge – to increase its mobility across a biological membrane and, through electrorepulsion, drive a like-charged drug substance into the ocular tissue.